According to Qingyun Biology xiaobian understand: last year, in addition to traditional Chinese medicine, all kinds of exports of traditional Chinese medicine have shown a growth trend. The export of plant extracts accounted for 56.8% of the export of TRADITIONAL Chinese medicine.
Exports of health care products and Chinese patent medicine both reached US $140 million, up 13.0% and 5.7% year on year, both maintaining a steady trend. However, the increase in export of health care products and Chinese patent medicine was due to the increase in prices. The export volume of health care products and Chinese patent medicine both showed a downward trend, with a year-on-year decline of 7.6% and 3.0%. The main reasons are:
1.
Traditional market is still the main force driving the export growth of traditional Chinese medicin
China's export of TRADITIONAL Chinese medicine to 154 countries and regions, Asia is still the main export market of traditional Chinese medicine, China's export of traditional Chinese medicine to Asian countries and regions reached us $1.16 billion, up 9.5% year on year, accounting for 60.7% of China's export of traditional Chinese medicine. Among them, Hong Kong, Japan, Malaysia, South Korea and Indonesia are the main target markets. Hong Kong remained the mainland's top market for traditional Chinese medicine exports, with exports falling slightly by 5.3 per cent year-on-year to $300m. The US is the second and most important market for traditional Chinese medicine exports. The growth rate has been high in recent years. In the first half of last year, China exported 270 million US dollars of traditional Chinese medicine to the United States, up 17.2% year on year, accounting for 14.1% of China's traditional Chinese medicine exports. Chinese herbal medicine products exported to the United States are mainly plant extracts, accounting for 78.2%.
2. The import of traditional Chinese medicine products stopped falling and picked up
The import of Traditional Chinese medicine products was 510 million US dollars, with a year-on-year growth of 2.3%, and the export volume turned from decline to rise (in 2014, the import of traditional Chinese medicine decreased by 16.8% year-on-year). However, only plant extract imports of all commodities increased significantly, while other products continued to decline significantly. Among them, the import of plant extracts was 210 million US dollars, with a year-on-year increase of 48.0%. The import varieties were mainly peppermint oil and other essential oil products and licorice products. The import of Chinese patent medicine reached 130 million US dollars, 19.2% lower than that of the previous year. The import of health products was US $71.06 million, down 19.3% year on year. The import of Chinese medicinal materials was 96.11 million US dollars, down 9.8 percent year-on-year. The main reason for the decline in the import of Chinese medicinal materials was the decline in the quantity and price of bulk varieties. American ginseng, for example, imported 291 tons in the first half of the year, down 21.0% year on year, the price fell 14.0% year on year; Licorice imported 8,772 tons, 38.9% lower than the same period last year, and the price fell 8.1%.
Plant extracts promote the export of domestic traditional Chinese medicine
"Flight check" is almost the most popular topic in 2015, the CFDA were released 22 check "flying" notice, involving Chinese medicine reported 20 times, Chinese medicine yinpian industry most affected, not only involves several Chinese medicinal materials professional market, also includes more than 50 Chinese medicine yinpian enterprise's GMP certificate retracted, a large number of ginkgo biloba extract related businesses surveyed, including many plant extracts export enterprises.
Is not only the domestic, in the first half of the United States, New York state attorney general's office according to the results of DNA detection method to check the nutrition brand GNC, Walgreens drugstore, supermarket chain wal-mart and Target, sent a letter to America's four big retailers, according to sell part of its health care products do not contain label claims, and even for allergic people to potentially dangerous plant additives, ask its shelves immediately. Although the two sides later reached an agreement to restore the products to the shelves, there was widespread public concern about the safety risks of dietary supplements and the relative inadequacy of the U.S. dietary supplement regulatory regime.
Against the unfavorable domestic and foreign trade environment, the foreign trade of Traditional Chinese medicine still achieved good performance in the first half of the year. It is expected that the foreign trade of traditional Chinese medicine will maintain rapid development in the second half of the year, and the new policy in medicine is likely to bring positive benefits to the industrial development.